Coverage
-
March 29, 2016
After tentatively green-lighting investors' claims earlier this year that Arrowhead Research Corp. overstated Hepatitis B vaccine trial results, a California federal judge tossed the proposed class action on Tuesday, saying the suit was too thin on specifics.
1 other articles on this case.
View all »